- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07783880
Investigation to Assess the Effects of Drug-COATED Balloons for Treatment of Plaques Erosions Causing Acute Coronary Syndromes (DCB-PE)
Drug-COATED Balloons for Treatment of Plaques Erosions Causing Acute Coronary Syndromes
Drug eluting balloon angioplasty might be a better alternative than medical treatment or stenting in subjects with plaque erosion, which is the second most common cause of myocardial infarction.
The main objective of this pilot study is to gain clear insights on the effect of percutaneous coronary intervention (PCI) with size matched DCB (SeQuent) as compared to treatment with GP IIbIIIa inhibitor or heparin & dual antiplatelet therapy in a predominantly Caucasian population at 2 days and at 1 year after the procedure.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Prof. Elvin Kedhi, MD PhD
- Telefonnummer: +1 514-934-1934
- E-mail: ekedhi@me.com
Studiesteder
-
-
-
Lubin, Polen
- Miedziowe Centrum Zdrowia SA
-
Kontakt:
- Dr. hab. n. med. Adrian Wlodarczak
- Telefonnummer: +48 76 846 03 00
- E-mail: wlodarczakadrian@gmail.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Patients aged ≥18 years presenting with MI where the culprit de-novo (stent restenosis/thrombosis excluded) lesion has a Thrombolysis in Myocardial Infarction (TIMI) flow of ≥ I with signs of thrombus on angiographic (or CCTA followed by conventional coronary angiography) evaluation located in a native coronary artery (a by-pass graft vessel excluded) addressable by PCI;
OCT criteria (all 4 should be present):
- Presence of thrombus
- Absence of an overt ruptured plaque flap
- Area of stenosis of ≥ 50%
- Presence of atherosclerotic, predominantly lipidic or fibrotic plaque underneath (absence of major calcifications or calcified noduli)
Exclusion Criteria:
- Culprit lesion located or extending in the Left Main coronary artery;
- Presence of large coronary aneurysms;
- Large thrombus burden (extending for more than > 15 mm);
- Patients with severe tortuous lesions (OCT judged not possible);
- Spontaneous coronary dissection is suspected;
- Renal insufficiency (Glomerular Filtration Rate (GFR) < 29 ml/min/1.73m2; Kidney Disease Outcomes Quality Initiative (KDOQI) stage 4 and 5);
- Life expectancy less than 2 years;
- Pregnant or lactating women;
- Patients currently participating in another trial;
Patients that are unable or unwilling to provide consent;
OCT exclusion criteria:
- Overt plaque rupture;
- Thrombosed protruding calcified noduli;
- Predominantly calcific lesions with calcium arc > 180° in the target segment;
- Presence of calcium plaque of > 0.4 mm thick;
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: PCI with size matched DCB
PCI with size matched drug-coated balloon
|
Subjects will be treated with PCI with size matched DCB (SeQuent)
|
|
Placebo komparator: GP IIbIIIa inhibitor or heparin & dual antiplatelet therapy
|
GP IIbIIIa inhibitor or heparin & dual antiplatelet therapy
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Optical Coherence Tomography (OCT)-assessed Minimum Lumen Area (MLA) during the control procedure
Tidsramme: Day 2-3
|
Day 2-3
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Coronary Computed Tomography Angiography (CCTA) assessed MLA at 1-year
Tidsramme: 1 Year
|
1 Year
|
|
|
Target Lesion Failure (TLF) at 1-year
Tidsramme: 1 Year
|
TLF is defined as Cardiac death, Target Vessel-MI (TV-MI), and Clinically-Driven Target Lesion Revascularization (CD-TLR)
|
1 Year
|
|
TLF at 2-years
Tidsramme: 2 Years
|
TLF is defined as Cardiac death, TV-MI, and CD-TLR
|
2 Years
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
CCTA-assessed plaque burden at baseline
Tidsramme: Baseline
|
Baseline
|
|
|
CCTA-assessed plaque burden post PCI
Tidsramme: 1 Week
|
1 Week
|
|
|
CCTA-assessed plaque burden at 1-year
Tidsramme: 1 Year
|
1 Year
|
|
|
CCTA-assessed lipid pool volume at baseline
Tidsramme: Baseline
|
Baseline
|
|
|
CCTA-assessed lipid pool volume post PCI
Tidsramme: 1 Week
|
1 Week
|
|
|
CCTA-assessed lipid pool volume at 1-year
Tidsramme: 1 Year
|
1 Year
|
|
|
Computed Tomography Fractionated Flow Reserve (CT-FFR) at baseline
Tidsramme: Baseline
|
Baseline
|
|
|
CT-FFR at 1-year
Tidsramme: 1 Year
|
1 Year
|
|
|
Shear stress at lesion level at baseline measured by Elucid software
Tidsramme: Baseline
|
Baseline
|
|
|
Shear stress at lesion level at 1-year measured by Elucid software
Tidsramme: 1 Year
|
1 Year
|
|
|
OCT-assessed thrombus volume at baseline
Tidsramme: Baseline
|
Baseline
|
|
|
OCT-assessed thrombus volume at control procedure
Tidsramme: Day 2-3
|
Day 2-3
|
|
|
OCT-assessed area of stenosis post index procedure
Tidsramme: Periprocedural
|
Periprocedural
|
|
|
OCT-assessed area of stenosis post control procedure
Tidsramme: Day 2-3
|
Day 2-3
|
|
|
OCT-assessed lumen gain
Tidsramme: Periprocedural and Day 2-3
|
Difference between control and index MLA
|
Periprocedural and Day 2-3
|
|
OCT-assessed lipid arc at control procedure
Tidsramme: Day 2-3
|
Day 2-3
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Karsygdomme
- Hjerte-kar-sygdomme
- Patologiske processer
- Hjertesygdomme
- Infarkt
- Nekrose
- Myokardieiskæmi
- Iskæmi
- Patologiske tilstande, tegn og symptomer
- Myokardieinfarkt
- Kirurgiske procedurer, operative
- Endovaskulære procedurer
- Vaskulære kirurgiske procedurer
- Kardiovaskulære kirurgiske procedurer
- Minimalt invasive kirurgiske procedurer
- Kulhydrater
- Glycosaminoglycans
- Polysaccharider
- Heparin
- Perkutan koronar intervention
Andre undersøgelses-id-numre
- 3W-RCG-2
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .